BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25435115)

  • 1. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions.
    Hijiya N; Millot F; Suttorp M
    Pediatr Clin North Am; 2015 Feb; 62(1):107-19. PubMed ID: 25435115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Oyekunle A; Zander AR; Binder M; Ayuk F; Zabelina T; Christopeit M; Stübig T; Alchalby H; Schafhausen P; Lellek H; Wolschke C; Müller I; Bacher U; Kröger N
    Ann Hematol; 2013 Apr; 92(4):487-96. PubMed ID: 23250623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myeloid leukemia (CML) in children: classical and newer therapeutic approaches.
    Ampatzidou M; Papadhimitriou SI; Goussetis E; Panagiotou JP; Papadakis V; Polychronopoulou S
    Pediatr Hematol Oncol; 2012 Aug; 29(5):389-94. PubMed ID: 22690835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.
    Hijiya N; Schultz KR; Metzler M; Millot F; Suttorp M
    Blood; 2016 Jan; 127(4):392-9. PubMed ID: 26511135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of tyrosine kinase inhibitor on outcome of allogeneic hematopoietic stem cell transplant for the treatment of chronic myeloid leukaemia].
    Xu L; Ma Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):94-5. PubMed ID: 24606642
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
    Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
    Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advancements in the treatment of chronic myelogenous leukemia.
    O'Dwyer ME; Mauro MJ; Druker BJ
    Annu Rev Med; 2002; 53():369-81. PubMed ID: 11818480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
    Maziarz RT
    Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current role of stem cell transplantation in chronic myeloid leukaemia.
    Gratwohl A; Heim D
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):431-43. PubMed ID: 19959092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.
    Cea M; Cagnetta A; Garuti A; Cirmena G; Rocco I; Moran E; Grillo V; Ballestrero A; Patrone F; Nencioni A
    J BUON; 2009; 14(4):565-73. PubMed ID: 20148444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
    Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
    Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Xu LP; Huang XJ
    Chin Med J (Engl); 2013 Feb; 126(4):768-74. PubMed ID: 23422204
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic myelogenous leukemia, BCR-ABL1+.
    Vardiman JW
    Am J Clin Pathol; 2009 Aug; 132(2):250-60. PubMed ID: 19605820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in hematopoietic stem cell transplantation in chronic myeloid leukemia.
    Veldman R; El Rassi F; Holloway S; Langston A; Khoury HJ
    Discov Med; 2013 Oct; 16(88):179-86. PubMed ID: 24099673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.
    de la Fuente J; Baruchel A; Biondi A; de Bont E; Dresse MF; Suttorp M; Millot F;
    Br J Haematol; 2014 Oct; 167(1):33-47. PubMed ID: 24976289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?
    Mauro MJ; Maziarz RT
    Mayo Clin Proc; 2006 Mar; 81(3):404-16. PubMed ID: 16529146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular monitoring of response in patients with chronic myeloid leukemia.
    Kolibaba KS
    Manag Care; 2013 Jul; 22(7):40, 50-61. PubMed ID: 23936973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.